Madrigal Pharmaceuticals, Inc. (MDGL)
| Market Cap | 1.31B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -255.90M |
| Shares Out | 17.10M |
| EPS (ttm) | -14.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 181,294 |
| Open | 72.47 |
| Previous Close | 73.34 |
| Day's Range | 72.47 - 78.12 |
| 52-Week Range | 52.33 - 105.93 |
| Beta | 1.04 |
| Analysts | Buy |
| Price Target | 159.04 (+107.3%) |
| Earnings Date | Aug 3, 2022 |
About MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for MDGL stock is "Buy." The 12-month stock price forecast is 159.04, which is an increase of 107.33% from the latest price.
News
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
CONSHOHOCKEN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis...
Trial Results Set to Make or Break Small-Cap Pharma Stocks
One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration...
Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) presented multiple resmetirom abstracts at the European Association for the Study of the Liver's International Liver Congress. The data included new details o...
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL's International...
CONSHOHOCKEN, Pa., June 25, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis...
Madrigal Pharmaceuticals Supports International NASH Day on June 9
Company expands its partnerships with leading patient advocacy groups to improve NASH education and patient care Company expands its partnerships with leading patient advocacy groups to improve NASH edu...
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
CONSHOHOCKEN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatit...
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
CONSHOHOCKEN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatiti...
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results
Company to host conference call at 8:00 AM ET, May 9th, 2022
Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepati...
Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financi...
CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatiti...
3 Graham's Lost Formula Stocks to Consider for February
After seeing a sell-off for most of January, two market indexes rose for the fourth day in a row on Wednesday. The S&P 500 Index was up 13.95 points, or 0.31%, while the tech-heavy Nasdaq Composite gain...
Why Madrigal Pharmaceuticals Stock Briefly Spiked Today
A positive data readout from a phase 3 clinical trial propelled the drugmaker's shares higher.
Madrigal Pharma's Kidney Disease Candidate Improves Liver, Cardiovascular Health
Madrigal Pharmaceuticals Inc MDGL has announced topline data from Phase 3 MAESTRO-NAFLD-1 safety study of resmetirom. [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.
Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistica...
Primary and key secondary endpoints from the double-blind placebo-controlled 969-patient MAESTRO-NAFLD-1 safety study were achieved and demonstrate that resmetirom:
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, ...
CONSHOHOCKEN, Pa., Jan. 30, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, plans...
3 Biotech Stocks With Major Catalysts in January
Binary events on the way could send these drugmaker stocks through the roof, or push them down in the dirt.
Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom
Company now expects to release topline 52-week results from MAESTRO-NAFLD-1 in January 2022 Company now expects to release topline 52-week results from MAESTRO-NAFLD-1 in January 2022
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
CONSHOHOCKEN, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty ...
Madrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results
Several abstracts with data from the open-label arm of the Phase 3 MAESTRO-NAFLD-1 study accepted for presentation at AASLD's upcoming The Liver Meeting® 2021 Several abstracts with data from the open-l...
Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation's Screening Fund to Improve Diagnosis and Stagin...
In recognition of Liver Awareness Month, Madrigal and Fatty Liver Foundation Ring Nasdaq Closing Bell to Increase Awareness of NAFLD/NASH In recognition of Liver Awareness Month, Madrigal and Fatty Live...
Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update
CONSHOHOCKEN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reports today its second quarter 2021 financial results and provides a summary of corporate accomplishme...
Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development Officer
CONSHOHOCKEN, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with h...
Here's Why Madrigal (MDGL) is Poised for a Turnaround After Losing 14.9% in 4 Weeks
Madrigal (MDGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co...
Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3...
CONSHOHOCKEN, Pa., July 13, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first patient dosed in a planned 52-week open label active treatment extension study...
Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-N...
CONSHOHOCKEN, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today achievement of the planned target enrollment in the Phase 3 clinical trial, MAESTRO-NASH...